A Study of Tecogalan Sodium
NCT00002342 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2005-06-24
Summary
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
Conditions
- Sarcoma, Kaposi
- HIV Infections
Interventions
- DRUG
-
Tecogalan sodium
Sponsors & Collaborators
-
Daiichi Pharmaceuticals
lead INDUSTRY
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.
NCT00195325 ·Status: TERMINATED ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00003709 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating TTI-237 in Advanced Malignant Solid Tumors
NCT00195247 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
NCT03232593 ·Status: COMPLETED
-
MEN-10755 in Treating Patients With Solid Tumors
NCT00003982 ·Status: COMPLETED ·Phase: PHASE1
-
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
NCT00820560 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies
NCT01335256 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
NCT06403436 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of HS-10342 in Patients With Advanced Solid Tumor
NCT04060511 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
NCT00094159 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors
NCT03934359 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
NCT06564272 ·Status: RECRUITING ·Phase: PHASE2
-
AZD1152 in Patients With Advanced Solid Malignancies
NCT00338182 ·Status: COMPLETED ·Phase: PHASE1
-
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
NCT00608361 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Dasatinib in Patients With Advanced Solid Tumors
NCT00162214 ·Status: TERMINATED ·Phase: PHASE1
-
A Trial of TAS-114 in Combination With S-1
NCT02454062 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors
NCT04226066 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
NCT00292864 ·Status: COMPLETED ·Phase: PHASE1
-
SJG-136 in Treating Patients With Advanced Solid Tumors
NCT00103220 ·Status: COMPLETED ·Phase: PHASE1
-
Study of DS-1123a in Advanced Solid Tumours
NCT02690337 ·Status: COMPLETED ·Phase: PHASE1
-
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
NCT00871559 ·Status: COMPLETED ·Phase: PHASE1
-
Decitabine in Treating Patients With Advanced Solid Tumors
NCT00030615 ·Status: COMPLETED ·Phase: PHASE1
-
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
NCT07035249 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
NCT01188252 ·Status: COMPLETED ·Phase: PHASE1
-
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00023816 ·Status: UNKNOWN ·Phase: PHASE1